615 related articles for article (PubMed ID: 10727301)
1. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
[TBL] [Abstract][Full Text] [Related]
2. Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood.
Chimanovitch I; Hamm H; Georgi M; Kroiss M; Stolz W; Apitz C; Bröcker EB; Zillikens D
Arch Dermatol; 2000 Apr; 136(4):527-32. PubMed ID: 10768652
[TBL] [Abstract][Full Text] [Related]
3. IgE autoantibodies against the intracellular domain of BP180.
Dresow SK; Sitaru C; Recke A; Oostingh GJ; Zillikens D; Gibbs BF
Br J Dermatol; 2009 Feb; 160(2):429-32. PubMed ID: 18808416
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
5. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
7. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
8. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.
Fairley JA; Fu CL; Giudice GJ
J Invest Dermatol; 2005 Sep; 125(3):467-72. PubMed ID: 16117787
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180.
Zillikens D; Caux F; Mascaro JM; Wesselmann U; Schmidt E; Prost C; Callen JP; Bröcker EB; Diaz LA; Giudice GJ
J Invest Dermatol; 1999 Jul; 113(1):117-21. PubMed ID: 10417629
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
[TBL] [Abstract][Full Text] [Related]
11. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins.
Nakatani C; Muramatsu T; Shirai T
Br J Dermatol; 1998 Sep; 139(3):365-70. PubMed ID: 9767278
[TBL] [Abstract][Full Text] [Related]
12. IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid.
Zuo Y; Evangelista F; Culton D; Guilabert A; Lin L; Li N; Diaz L; Liu Z
J Autoimmun; 2016 Sep; 73():111-9. PubMed ID: 27377454
[TBL] [Abstract][Full Text] [Related]
13. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.
Fania L; Caldarola G; Müller R; Brandt O; Pellicano R; Feliciani C; Hertl M
Clin Immunol; 2012 Jun; 143(3):236-45. PubMed ID: 22534318
[TBL] [Abstract][Full Text] [Related]
14. A case of bullous pemphigoid associated with autoantibodies targeting antigenic sites other than the NC16a domain of BP180.
Shinojima Y; Ochiai T; Kawamura A; Arakawa H; Fukuda K; Hashimoto T
Clin Exp Dermatol; 2005 Sep; 30(5):503-5. PubMed ID: 16045678
[TBL] [Abstract][Full Text] [Related]
15. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid.
Dimson OG; Giudice GJ; Fu CL; Van den Bergh F; Warren SJ; Janson MM; Fairley JA
J Invest Dermatol; 2003 May; 120(5):784-8. PubMed ID: 12713582
[TBL] [Abstract][Full Text] [Related]
16. Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.
Emtenani S; Yuan H; Lin C; Pan M; Hundt JE; Schmidt E; Komorowski L; Stanley JR; Hammers CM
Br J Dermatol; 2019 May; 180(5):1099-1106. PubMed ID: 30315657
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of immunoglobulins G1 and G4 targeting the non-collagenous 16A domain of BP180 reflect bullous pemphigoid activity and predict bad prognosis.
Zhou XP; Liu B; Xu Q; Yang Y; He CX; Zuo YG; Liu YH
J Dermatol; 2016 Feb; 43(2):141-8. PubMed ID: 26300465
[TBL] [Abstract][Full Text] [Related]
18. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180.
Schmidt E; Skrobek C; Kromminga A; Hashimoto T; Messer G; Bröcker EB; Yancey KB; Zillikens D
Br J Dermatol; 2001 Nov; 145(5):778-83. PubMed ID: 11736901
[TBL] [Abstract][Full Text] [Related]
19. Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity.
Emtenani S; Linnemann BE; Recke A; von Georg A; Goletz S; Schmidt E; van Beek N
J Dermatol Sci; 2024 May; 114(2):64-70. PubMed ID: 38582700
[TBL] [Abstract][Full Text] [Related]
20. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid.
Di Zenzo G; Thoma-Uszynski S; Fontao L; Calabresi V; Hofmann SC; Hellmark T; Sebbag N; Pedicelli C; Sera F; Lacour JP; Wieslander J; Bruckner-Tuderman L; Borradori L; Zambruno G; Hertl M
Clin Immunol; 2008 Sep; 128(3):415-26. PubMed ID: 18571472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
